Primary graft dysfunction following lung transplantation: From pathogenesis to future frontiers.

Area of Science:

• Transplantation Medicine
• Pulmonary Medicine
• Immunology

Background:

• Lung transplantation is the definitive treatment for end-stage lung disease.
• Primary graft dysfunction (PGD) is a major cause of mortality within 90 days and one year post-transplant.
• PGD is a spectrum of lung injury with varying severity.

Purpose of the Study:

• To provide an in-depth analysis of PGD epidemiology, pathophysiology, risk factors, and outcomes.
• To examine current diagnostic criteria for PGD and compare them to previous definitions.
• To highlight challenges in chronic lung allograft dysfunction and explore novel therapies like ex-vivo lung perfusion.

Main Methods:

• Literature review and analysis of current research on primary graft dysfunction.
• Examination of epidemiological data and risk factors associated with PGD.
• Review of diagnostic criteria, outcomes, and emerging therapeutic interventions.

Main Results:

• PGD is a critical determinant of early mortality after lung transplantation.
• Understanding PGD's spectrum and risk factors is crucial for patient management.
• Novel therapies, including ex-vivo lung perfusion, show promise in addressing PGD and chronic lung allograft dysfunction.

Conclusions:

• Despite challenges, advancements in research and technology offer hope for improved diagnostics and therapeutics for PGD.
• Mitigating PGD is essential for improving long-term outcomes in lung transplant recipients.
• Continued investigation into PGD and chronic lung allograft dysfunction is vital for the future of lung transplantation.